EDITAS MEDICINE, INC. Assets, Fair Value Disclosure
EDITAS MEDICINE, INC. (EDIT) had Assets, Fair Value Disclosure of $214.31 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Assets, Fair Value Disclosure $214.31M.
- 2026-03-31: Assets, Fair Value Disclosure $126.32M.
- 2025-12-31: Assets, Fair Value Disclosure $149.31M.
- 2024-12-31: Assets, Fair Value Disclosure $273.79M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $214.31M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $126.32M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $149.31M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $273.79M 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |